Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.

Deshmukh V, O'Green AL, Bossard C, Seo T, Lamangan L, Ibanez M, Ghias A, Lai C, Do L, Cho S, Cahiwat J, Chiu K, Pedraza M, Anderson S, Harris R, Dellamary L, Kc S, Barroga C, Melchior B, Tam B, Kennedy S, Tambiah J, Hood J, Yazici Y.

Osteoarthritis Cartilage. 2019 May 25. pii: S1063-4584(19)30994-X. doi: 10.1016/j.joca.2019.05.006. [Epub ahead of print]

2.

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab.

Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Simsek I.

Biologics. 2018 Oct 25;12:127-134. doi: 10.2147/BTT.S172337. eCollection 2018.

3.

Editorial: A review of vasculitis 2019: an introduction.

Yazici H, Yazici Y.

Curr Opin Rheumatol. 2019 Jan;31(1):1-2. doi: 10.1097/BOR.0000000000000565. No abstract available.

PMID:
30407227
4.

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison.

Maksymowych WP, Strand V, Nash P, Yazici Y, Thom H, Hunger M, Kalyvas C, Gandhi KK, Porter B, Jugl SM.

Eur J Rheumatol. 2018 Dec;5(4):216-223. doi: 10.5152/eurjrheum.2018.18162. Epub 2018 Oct 30.

5.

A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population.

Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Mutlu EA, Simsek I.

Biologics. 2018 Oct 2;12:97-106. doi: 10.2147/BTT.S172241. eCollection 2018.

6.

Assessing the possible association of anti-TNF use with new malignancies: A neglected methodological consideration.

Ozguler Y, Yazici Y, Hatemi G, Tascilar K, Yazici H.

Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):894-901. doi: 10.1002/pds.4579. Epub 2018 Jun 19. No abstract available.

PMID:
29920843
7.

Application of a Portable Multi-Analyte Biosensor for Organic Acid Determination in Silage.

Pilas J, Yazici Y, Selmer T, Keusgen M, Schöning MJ.

Sensors (Basel). 2018 May 8;18(5). pii: E1470. doi: 10.3390/s18051470.

8.

Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.

Strand V, Lee EB, Yazici Y, Dikranian A, Wilkinson B, Takiya L, Zang C, Bananis E, Bergman MJ.

Clin Rheumatol. 2018 Aug;37(8):2043-2053. doi: 10.1007/s10067-018-4077-3. Epub 2018 Apr 14.

9.

Behçet syndrome: a contemporary view.

Yazici H, Seyahi E, Hatemi G, Yazici Y.

Nat Rev Rheumatol. 2018 Jan 24;14(2):119. doi: 10.1038/nrrheum.2018.3.

PMID:
29362466
10.

Behçet syndrome: a contemporary view.

Yazici H, Seyahi E, Hatemi G, Yazici Y.

Nat Rev Rheumatol. 2018 Feb;14(2):107-119. doi: 10.1038/nrrheum.2017.208. Epub 2018 Jan 3. Review. Erratum in: Nat Rev Rheumatol. 2018 Jan 24;14 (2):119.

PMID:
29296024
11.

MDHAQ/RAPID3 scores in patients with osteoarthritis are similar to or higher than in patients with rheumatoid arthritis: a cross-sectional study from current routine rheumatology care at four sites.

El-Haddad C, Castrejon I, Gibson KA, Yazici Y, Bergman MJ, Pincus T.

RMD Open. 2017 Jul 18;3(1):e000391. doi: 10.1136/rmdopen-2016-000391. eCollection 2017.

12.

Vasculitis 2018: the bench and the bedside.

Yazici H, Yazici Y.

Curr Opin Rheumatol. 2018 Jan;30(1):1-3. doi: 10.1097/BOR.0000000000000462. No abstract available.

PMID:
29035929
13.

A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial.

Curtis JR, Herrem C, Ndlovu 'N, O'Brien C, Yazici Y.

Arthritis Res Ther. 2017 Sep 29;19(1):215. doi: 10.1186/s13075-017-1412-z.

14.

Biomarkers in vasculitis.

Hatemi G, Esatoglu SN, Yazici Y.

Curr Opin Rheumatol. 2018 Jan;30(1):30-35. doi: 10.1097/BOR.0000000000000447. Review.

PMID:
28937415
15.

A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.

Deshmukh V, Hu H, Barroga C, Bossard C, Kc S, Dellamary L, Stewart J, Chiu K, Ibanez M, Pedraza M, Seo T, Do L, Cho S, Cahiwat J, Tam B, Tambiah JRS, Hood J, Lane NE, Yazici Y.

Osteoarthritis Cartilage. 2018 Jan;26(1):18-27. doi: 10.1016/j.joca.2017.08.015. Epub 2017 Sep 6.

16.

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.

Yazici Y, McAlindon TE, Fleischmann R, Gibofsky A, Lane NE, Kivitz AJ, Skrepnik N, Armas E, Swearingen CJ, DiFrancesco A, Tambiah JRS, Hood J, Hochberg MC.

Osteoarthritis Cartilage. 2017 Oct;25(10):1598-1606. doi: 10.1016/j.joca.2017.07.006. Epub 2017 Jul 13.

17.
18.

Adherence to guidelines for the treatment of Behçet's syndrome in New York and Amsterdam.

Kerstens FG, Turkstra F, Atalay S, van Vugt RM, Swearingen CJ, Yazici Y.

Clin Exp Rheumatol. 2017 Nov-Dec;35 Suppl 108(6):55-59. Epub 2017 Apr 13.

19.

Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016.

Hatemi G, Meara A, Ozguler Y, Direskeneli H, Mahr A, Easley E, Gurcan M, Davis T, Gul A, Yazici Y, Zottenberg K, Esatoglu SN, Erer B, Kamali S, Yazici H, Cronholm PF, Merkel PA.

J Rheumatol. 2017 Nov;44(11):1750-1753. doi: 10.3899/jrheum.161352. Epub 2017 Apr 1.

PMID:
28365574
20.

Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.

Grayson PC, Yazici Y, Merideth M, Sen HN, Davis M, Novakovich E, Joyal E, Goldbach-Mansky R, Sibley CH.

Arthritis Res Ther. 2017 Mar 24;19(1):69. doi: 10.1186/s13075-017-1222-3.

21.

The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey.

Nikiphorou E, Galloway J, van Riel P, Yazici Y, Haugeberg G, Ostor A, Gogus F, Kauppi M, Sokka T; QUEST-RA.

Clin Exp Rheumatol. 2017 May-Jun;35(3):477-483. Epub 2017 Jan 27.

PMID:
28134086
22.

[Investigation of the frequency and distribution of beta-lactamase genes in the clinical isolates of Acinetobacter baumannii collected from different regions of Turkey: a multicenter study].

Beriş FŞ, Budak EE, Gülek D, Uzun A, Çizmeci Z, Mengeloğlu FZ, Direkel Ş, Çetinkol Y, Ay Altıntop Y, Iraz M, Dal T, Say Coşkun SU, Balcı PÖ, Kayman T, Çalışkan A, Yazıcı Y, Tosun İ, Ertürk A, Çopur Çiçek A.

Mikrobiyol Bul. 2016 Oct;50(4):511-521. Turkish.

23.

Diet quality of individuals with rheumatoid arthritis using the Healthy Eating Index (HEI)-2010.

Berube LT, Kiely M, Yazici Y, Woolf K.

Nutr Health. 2017 Mar;23(1):17-24. doi: 10.1177/0260106016688223. Epub 2017 Jan 22.

PMID:
28112038
24.

Use of Biologic Therapy in Racial Minorities With Rheumatoid Arthritis From 2 US Health Care Systems.

Kerr GS, Swearingen C, Mikuls TR, Yazici Y.

J Clin Rheumatol. 2017 Jan;23(1):12-18. doi: 10.1097/RHU.0000000000000472.

PMID:
28002151
26.

An update on vasculitides - lumps and constructs.

Yazici H, Yazici Y.

Curr Opin Rheumatol. 2017 Jan;29(1):1-3. No abstract available.

PMID:
27906751
27.

Behcet's syndrome in nonendemic regions.

Leccese P, Yazici Y, Olivieri I.

Curr Opin Rheumatol. 2017 Jan;29(1):12-16. Review.

PMID:
27684358
28.

Pragmatic assessment of exercise in routine care using an MDHAQ: associations with changes in RAPID3 and other clinical variables.

Castrejón I, Yazici Y, Celik S, Pincus T.

Arthritis Res Ther. 2016 Sep 6;18:199. doi: 10.1186/s13075-016-1095-x.

29.

Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration.

Schiff M, Weinblatt ME, Valente R, Citera G, Maldonado M, Massarotti E, Yazici Y, Fleischmann R.

RMD Open. 2016 Apr 19;2(1):e000210. doi: 10.1136/rmdopen-2015-000210. eCollection 2016.

32.

Vasculitis: a brief update.

Yazici H, Yazici Y.

Curr Opin Rheumatol. 2016 Jan;28(1):1-2. doi: 10.1097/BOR.0000000000000242. No abstract available.

PMID:
26555453
33.

Diagnosis and/or classification of vasculitis: different?

Yazici H, Yazici Y.

Curr Opin Rheumatol. 2016 Jan;28(1):3-7. doi: 10.1097/BOR.0000000000000230. Review.

PMID:
26555449
34.

Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis.

Buttgereit F, Kent JD, Holt RJ, Grahn AY, Rice P, Alten R, Yazici Y.

Bull Hosp Jt Dis (2013). 2015 Jul;73(3):168-77.

36.

A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol.

Curtis JR, Churchill M, Kivitz A, Samad A, Gauer L, Gervitz L, Koetse W, Melin J, Yazici Y.

Arthritis Rheumatol. 2015 Dec;67(12):3104-12. doi: 10.1002/art.39322.

37.

Diagnostic Criteria as Separate From Classification Criteria: A Perpetual Motion Machine? Comment on the Article by Aggarwal et al.

Yazici H, Hatemi G, Yazici Y.

Arthritis Care Res (Hoboken). 2016 Jul;68(7):1049. doi: 10.1002/acr.22718. No abstract available.

38.

Pulmonary artery aneurysms in Behçet's syndrome: a review of the literature with emphasis on geographical differences.

Celik S, Yazici Y, Sut N, Yazici H.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S54-9. Epub 2015 Jul 23. Review.

PMID:
26211653
39.

Evaluation of the medical malpractice cases concluded in the General Assembly of Council of Forensic Medicine.

Yazıcı YA, Şen H, Aliustaoğlu S, Sezer Y, İnce CH.

Ulus Travma Acil Cerrahi Derg. 2015 May;21(3):204-8. doi: 10.5505/tjtes.2015.24295.

40.

Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.

Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, Merkel PA, Calamia KT, Liu Z, Pineda L, Stevens RM, Yazici H, Yazici Y.

N Engl J Med. 2015 Apr 16;372(16):1510-8. doi: 10.1056/NEJMoa1408684.

41.

A patient-reported outcome measures-based composite index (RAPID3) for the assessment of disease activity in ankylosing spondylitis.

Cinar M, Yilmaz S, Cinar FI, Koca SS, Erdem H, Pay S, Dinc A, Yazici Y, Simsek I.

Rheumatol Int. 2015 Sep;35(9):1575-80. doi: 10.1007/s00296-015-3256-7. Epub 2015 Mar 21.

PMID:
25794571
42.

Are sample sizes of randomized clinical trials in rheumatoid arthritis too large?

Celik S, Yazici Y, Yazici H.

Eur J Clin Invest. 2014 Nov;44(11):1034-44. doi: 10.1111/eci.12337. Epub 2014 Oct 7. Review.

PMID:
25207845
43.

Identifying biomarkers: where is the scientific methodology? Comment on the article by Sanayama et Al.

Yazici Y.

Arthritis Rheumatol. 2014 Dec;66(12):3524. doi: 10.1002/art.38859. No abstract available.

44.

Erosions in rheumatoid arthritis: is there less here than meets the eye?

Yazici Y.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 87):S-7. Epub 2014 Aug 4. No abstract available.

PMID:
25152005
45.

Headache in Behçet's syndrome: review of literature and NYU Behçet's syndrome center experience.

Vishwanath V, Wong E, Crystal SC, Robbins MS, Filopoulos M, Lipton RB, Yazici Y, Kister I.

Curr Pain Headache Rep. 2014 Sep;18(9):445. doi: 10.1007/s11916-014-0445-0. Review.

PMID:
25091130
46.

MBDA: what is it good for?

Yazici Y, Swearingen CJ.

Ann Rheum Dis. 2014 Nov;73(11):e72. doi: 10.1136/annrheumdis-2014-206252. Epub 2014 Jul 23. No abstract available.

PMID:
25057179
47.

Behçet syndrome manifestations and activity in the United States versus Turkey -- a cross-sectional cohort comparison.

Sibley C, Yazici Y, Tascilar K, Khan N, Bata Y, Yazici H, Goldbach-Mansky R, Hatemi G.

J Rheumatol. 2014 Jul;41(7):1379-84. doi: 10.3899/jrheum.131227. Epub 2014 Jun 15.

48.

Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?

Fleischmann R, Yazici Y.

Ann Rheum Dis. 2014 Sep;73(9):e54. doi: 10.1136/annrheumdis-2014-205901. Epub 2014 Jun 3. No abstract available.

PMID:
24894190
49.

Ocular Involvement of Behçet's Syndrome: a Comprehensive Review.

Ozyazgan Y, Ucar D, Hatemi G, Yazici Y.

Clin Rev Allergy Immunol. 2015 Dec;49(3):298-306. doi: 10.1007/s12016-014-8425-z. Review.

PMID:
24828904
50.

Who decides if research will be published, authors or sponsors? Comment on the article by Curtis et al.

Yazici Y.

Arthritis Care Res (Hoboken). 2014 Aug;66(8):1270-1. doi: 10.1002/acr.22356. No abstract available.

Supplemental Content

Loading ...
Support Center